# CASCADE Coordinating Center

> **NIH NIH U24** · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · 2024 · $990,038

## Abstract

Project Summary/Abstract
Women living with HIV (WLWH) have a higher risk for acquisition, persistence, and progression of cervical
human papillomavirus (HPV) to precancerous lesions, which, in the absence of effective screening and
treatment services, can progress to invasive cancer at five-to-six times higher rates than in women without
HIV. The massive global mobilization of humanitarian resources spanning over the past couple of decades,
through initiatives such as the US President's Emergency Plan for AIDS Relief (PEPFAR), has resulted in
millions of WLWH in low- and middle-income countries (LMICs) now accessing affordable antiretroviral therapy
and consequently living longer lives. Yet, their risk for cervical cancer continues unabated since effective
screening and pre-cancer treatment services remain unavailable in most LMICs.
The HIV/Cervical Cancer Prevention “CASCADE” Clinical Trials Network plans to conduct pragmatic clinical
trials evaluating the effectiveness of clinically proven interventions to optimize the cervical cancer screening,
management, and pre-cancer treatment cascade for WLWH. These clinical trials will be conducted in intended-
use environments in resource-constrained settings in LMICs and in regions with health disparities in the United
States. The CASCADE Network will have four major scientific focus areas: increasing screening uptake,
improving management of screen positives, facilitating pre-cancer treatment access, and optimizing pre-cancer
treatment for cervical cancer prevention in WLWH. The CASCADE Network clinical trials will focus on the
measurement of the clinical effectiveness of interventions in intended use settings while gathering crucial
information informing the implementation and scale-up of such interventions across the cascade of screening
and pre-cancer treatment for WLWH. Such hybrid effectiveness-implementation designs will primarily focus on
clinical effectiveness endpoints such as HPV positivity rates and/or pre-cancer detection/incidence/recurrence
rates and will secondarily gather data on implementation-informing aspects such as costs, acceptability, and
intervention fidelity while studying implementation strategy.
To support the CASCADE Clinical Trials Network in partnership with the NCI's Division of Cancer Prevention,
CASCADE Research Bases and CASCADE Clinical Sites, the CASCADE Network Coordinating Center will (i)
provide overall network coordination and facilitate scientific review of network clinical trial concepts and
protocols, (ii) provide centralized support for data management for network clinical trials, and (iii) conduct
independent risk-appropriate auditing of network clinical trials. The CASCADE Network Coordinating Center
will serve as the organizational and coordination hub for the CASCADE Network and provide multi-disciplinary
expertise in program and operations management, clinical research informatics/information technology, and
clinical trials auditing.

## Key facts

- **NIH application ID:** 10848369
- **Project number:** 5U24CA275417-03
- **Recipient organization:** FRONTIER SCI & TECHNOLOGY RSCH FDN, INC
- **Principal Investigator:** Suzanne M. Siminski
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $990,038
- **Award type:** 5
- **Project period:** 2022-09-07 → 2027-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10848369

## Citation

> US National Institutes of Health, RePORTER application 10848369, CASCADE Coordinating Center (5U24CA275417-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10848369. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*